Vaccines for Preventing Clostridium Difficile Infection

September 27, 2017 | Technology Forecasts


Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.

Anticipated Utilization: 4(Expected to be used by 60% to 80% of eligible patients)

Eligible patients for vaccination would be aged 50 years or older anticipating inpatient treatment and at higher risk for Clostridium difficile infection (CDI). If the vaccines prove to be effective, third- party payers might require providers to vaccinate high-risk patients to obtain reimbursement for inpatient stays, procedures, and other services, promoting utilization. However, at least a one-month notice is needed before inpatient care, so the expected three doses can be administered; therefore, some patients may not have sufficient notice to obtain the vaccination regimen.

Estimated Adoption Status: 1 (Early adoption expected in 2+ years)

The most advanced vaccine candidate, ACAM-CDIFF™ (Sanofi Pasteur, SA, Swiftwater, PA, USA), is in phase III clinical development, and if topline data are positive, it could gain marketing approval as early as 2018. VLA84 (Valneva, SE, Lyon, France) and PF-06425090 (Pfizer, Inc., New York, NY, USA) are in earlier-development phases and...

Access Full Content

Contact us today at 610.825.6000.